(Q38074915)

28 August 2017

1 reference

title

The humanistic and economic burden of systemic lupus erythematosus : a systematic review (English)

1 reference

systemic lupus erythematosus

28 August 2017

1 reference

1 reference

Rachel Meacock

1

1 reference

28 August 2017

Nicola Dale

series ordinal

2

1 reference

28 August 2017

Mark J Harrison

series ordinal

3

1 reference

28 August 2017

publication date

1 January 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

31

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

49-61

1 reference

https://scigraph.springernature.com/pub.10.1007/s40273-012-0007-4

28 August 2017

exact match

0 references

cites work

Incidence of clinically diagnosed systemic lupus erythematosus 1992-1998 using the UK General Practice Research Database.

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0007-4

Incidence of systemic lupus erythematosus in the United Kingdom, 1990-1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0007-4

Prevalence of physician-diagnosed systemic lupus erythematosus in the United States: results from the third national health and nutrition examination survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0007-4

The prevalence of systemic lupus erythematosus in Northern Ireland

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0007-4

Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0007-4

Mortality and causes of death of 513 Danish patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0007-4

A review of health related quality of life in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0007-4

Re-evaluation of biologic therapies in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0007-4

Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0007-4

Quality of life and economic evaluation in SLE clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0007-4

Cost-of-illness studies in systemic lupus erythematosus: A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0007-4

Endpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0007-4

Generic versus disease-specific measures of health-related quality of life in systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0007-4

Psychometric properties of the EuroQol-5D and Short Form-6D in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0007-4

Construct and criterion validity of the short form-6D utility measure in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0007-4

Chronic conditions and health problems in rheumatic diseases: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, systemic lupus erythematosus, and fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0007-4

EQ-5D and SF-36 quality of life measures in systemic lupus erythematosus: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, and fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0007-4

The LupusQoL and associations with demographics and clinical measurements in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0007-4

LupusQoL-US benchmarks for US patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0007-4

Discordant assessment of lupus activity between patients and their physicians: the Singapore experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0007-4

The impact of flare on disease costs of patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0007-4

Systemic lupus erythematosus with neuropsychiatric manifestation incurs high disease costs: a cost-of-illness study in Hong Kong

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0007-4

A Canadian study of the total medical costs for patients with systemic lupus erythematosus and the predictors of costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0007-4

Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0007-4

Total costs and predictors of costs in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0007-4

Why health care costs more in the US: comparing health care expenditures between systemic lupus erythematosus patients in Stanford and Montreal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0007-4

The friction cost method for measuring indirect costs of disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0007-4

Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0007-4

Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0007-4

Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0007-4

The development of the L-QoL: a quality-of-life instrument specific to systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0007-4

Health state utility values: a description of their development and application for rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0007-4

Direct and indirect costs to employers of patients with systemic lupus erythematosus with and without nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0007-4

Quality of life measurement: bibliographic study of patient assessed health outcome measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0007-4

Quality of life over time in patients with systemic lupus erythematosus

21 January 2018

1 reference

12 December 2020

Towards a new approach for estimating indirect costs of disease

1 reference

12 December 2020

How does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses?

1 reference

12 December 2020

The impact of disease activity, treatment and disease severity on short-term costs of systemic lupus erythematosus

1 reference

12 December 2020

Decreasing costs and improving outcomes in systemic lupus erythematosus: using regression trees to develop health policy

1 reference

12 December 2020

The systemic lupus erythematosus Tri-Nation study: cumulative indirect costs

1 reference

12 December 2020

Can health utility measures be used in lupus research? A comparative validation and reliability study of 4 utility indices

1 reference

12 December 2020

Rating of arthritis health states by patients, physicians, and the general public. Implications for cost-utility analyses.

1 reference

12 December 2020

The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth

1 reference

12 December 2020

Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years

1 reference

12 December 2020

A comparison of the EuroQol-5D and the Health Utilities Index mark 3 in patients with rheumatic disease

1 reference

12 December 2020

The systemic lupus erythematosus Tri-nation Study: absence of a link between health resource use and health outcome

1 reference

12 December 2020

How to calculate indirect costs in economic evaluations

1 reference

12 December 2020

Underestimating the value of women: assessing the indirect costs of women with systemic lupus erythematosus. Tri-Nation Study Group.

1 reference

12 December 2020

An international perspective on the well being and health care costs for patients with systemic lupus erythematosus. Tri-Nation Study Group.

1 reference

12 December 2020

The prevalence and incidence of systemic lupus erythematosus in Nottingham, UK, 1989-1990

1 reference

12 December 2020

The validity and responsiveness of generic utility measures in rheumatoid arthritis: a review

1 reference

12 December 2020

The prevalence of diagnosed systemic lupus erythematosus in whites and Indian Asian immigrants in Leicester city, UK

1 reference

12 December 2020

Systemic lupus erythematosus--disease activity, severity, treatment and costs.

1 reference

12 December 2020

Using the Short Form 6D, as an overall measure of health, to predict damage accrual and mortality in patients with systemic lupus erythematosus: XLVII, results from a multiethnic US cohort

1 reference

12 December 2020

Factors predictive of overall health over the course of the disease in patients with systemic lupus erythematosus from the LUMINA cohort (LXII): use of the SF-6D.

1 reference

12 December 2020

10.1007/S40273-012-0007-4

Identifiers

DOI

1 reference

28 August 2017

1 reference